GoodRx Holdings, Inc.
About GoodRx Holdings, Inc.
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $796.9M
- Net income
- $30.4M
- Total assets
- $1.4B
- Market cap
- $897.5M
- Operating margin
- 11.0%
- Net margin
- 3.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $796.9M
- Operating expenses
- $709.4M
- Operating income
- $87.5M
- Income tax
- $26.1M
- Net income
- $30.4M
- EPS (basic)
- $0.09
- EPS (diluted)
- $0.09
Balance sheet
- Total assets
- $1.4B
- Current assets
- $643.1M
- Total liabilities
- $787.8M
- Current liabilities
- $246.0M
- Shareholders’ equity
- $616.3M
Cash flow
- Operating cash flow
- $167.9M
- Investing cash flow
- -$120.0M
- Financing cash flow
- -$234.5M
- Net cash flow
- -$186.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $897.5M
- P/E ratio
- 29.2
- EPS (diluted)
- $0.09
- Shares outstanding
- 341.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 23, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $30.4M in FY2025.
- Revenue grew 7% from FY2021 to FY2025.
- Trading 49% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 29.2.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review GoodRx Holdings, Inc..
Write a review
News about GoodRx Holdings, Inc.
News & sentiment via Polygon.io
